[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0808052A2 - Método para tratar ou prevenir inflamação sistêmica. - Google Patents

Método para tratar ou prevenir inflamação sistêmica.

Info

Publication number
BRPI0808052A2
BRPI0808052A2 BRPI0808052-6A2A BRPI0808052A BRPI0808052A2 BR PI0808052 A2 BRPI0808052 A2 BR PI0808052A2 BR PI0808052 A BRPI0808052 A BR PI0808052A BR PI0808052 A2 BRPI0808052 A2 BR PI0808052A2
Authority
BR
Brazil
Prior art keywords
treat
systemic inflammation
prevent systemic
infant
prevent
Prior art date
Application number
BRPI0808052-6A2A
Other languages
English (en)
Inventor
Robert Mcmahon
William Michael Russell
Udo Herz
Josef Neu
Original Assignee
Mead Johnson Nutrition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0808052(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mead Johnson Nutrition Co filed Critical Mead Johnson Nutrition Co
Publication of BRPI0808052A2 publication Critical patent/BRPI0808052A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0808052-6A2A 2007-02-28 2008-02-22 Método para tratar ou prevenir inflamação sistêmica. BRPI0808052A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90412207P 2007-02-28 2007-02-28
PCT/US2008/054710 WO2008106372A1 (en) 2007-02-28 2008-02-22 Method for treating or preventing systemic inflammation

Publications (1)

Publication Number Publication Date
BRPI0808052A2 true BRPI0808052A2 (pt) 2014-06-24

Family

ID=39469924

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0808052-6A2A BRPI0808052A2 (pt) 2007-02-28 2008-02-22 Método para tratar ou prevenir inflamação sistêmica.
BRPI0808145-0A BRPI0808145A2 (pt) 2007-02-28 2008-02-22 Produto contendo probiótico inativado para crianças ou lactentes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0808145-0A BRPI0808145A2 (pt) 2007-02-28 2008-02-22 Produto contendo probiótico inativado para crianças ou lactentes.

Country Status (14)

Country Link
US (2) US9408818B2 (pt)
EP (2) EP2124977B9 (pt)
CN (3) CN101636172A (pt)
AT (1) ATE544457T1 (pt)
BR (2) BRPI0808052A2 (pt)
CA (2) CA2676956C (pt)
ES (2) ES2388198T5 (pt)
HK (2) HK1136969A1 (pt)
MX (2) MX2009008875A (pt)
MY (2) MY151892A (pt)
PL (2) PL2114423T3 (pt)
RU (2) RU2468807C2 (pt)
TW (2) TWI494114B (pt)
WO (2) WO2008106372A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
BRPI0808052A2 (pt) * 2007-02-28 2014-06-24 Mead Johnson Nutrition Co Método para tratar ou prevenir inflamação sistêmica.
CA2707656C (en) * 2007-12-06 2018-05-22 Arla Foods Amba Probiotic bacteria and regulation of fat storage
CN102960447A (zh) * 2008-11-03 2013-03-13 雀巢产品技术援助有限公司 包含益生菌并改善睡眠模式的营养组合物
AU2010242955B2 (en) * 2009-04-29 2016-02-04 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
EP2251022A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
MY159273A (en) * 2009-05-11 2016-12-30 Nestec Sa Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
CA2786710C (en) 2010-01-19 2018-10-09 Abbott Laboratories Nutritional formulas containing synbiotics
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
EP2455093A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
EP2637513A2 (en) 2010-11-11 2013-09-18 Nestec S.A. Frozen confections containing probiotic micro-organisms
EP2455094A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101166798B1 (ko) 2011-12-19 2012-07-26 김대현 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물
US9545415B2 (en) * 2012-01-06 2017-01-17 Skyview Enterprise Ltd. Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation
US20130251829A1 (en) * 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN111676171B (zh) * 2013-08-09 2023-06-06 Ab-生物股份有限公司 用于婴儿过度啼哭的益生菌
CN105765058A (zh) * 2013-11-25 2016-07-13 雀巢产品技术援助有限公司 经热处理的乳酸双歧杆菌ncc2818制剂减轻变态反应的表现
RU2687038C1 (ru) * 2013-11-29 2019-05-06 Нестек С.А. Соответствующие возрастным потребностям питательные композиции с различным содержанием белка
PT3193901T (pt) 2014-12-23 2018-06-29 4D Pharma Res Ltd Polipéptido de pirina e modulação imunitária
EA202090948A1 (ru) 2014-12-23 2020-11-30 4Д Фарма Рисерч Лимитед Иммуномодуляция
ME03595B (me) 2015-06-15 2020-07-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
ES2748812T3 (es) 2015-06-15 2020-03-18 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3209310T (lt) 2015-11-20 2018-04-25 4D Pharma Research Limited Kompozicijos, apimančios bakterinius kamienus
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
BR112018067689A2 (pt) 2016-03-04 2019-01-08 4D Pharma Plc composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
ES2657665B1 (es) * 2016-09-05 2018-12-17 Pedro Jose DE LA FUENTE BLASCO Productos para la salud con probióticos inactivados y uso de dichos productos
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107115362A (zh) * 2017-04-28 2017-09-01 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗支气管哮喘制剂中的应用
MA48941A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
EP3804737B1 (en) 2017-06-14 2022-05-18 4D Pharma Research Limited Compositions comprising bacterial strains
SI3638271T1 (sl) 2017-06-14 2021-01-29 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
CN108041607A (zh) * 2017-12-26 2018-05-18 广州普正生物科技有限公司 一种护齿益生菌咀嚼软胶囊
RU2770463C1 (ru) * 2020-10-14 2022-04-18 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный технический университет им. И.И. Ползунова" (АлтГТУ) Способ производства мягкого сыра
TWI802009B (zh) * 2021-09-16 2023-05-11 創百股份有限公司 使用熱致死的乳酸菌菌株來治療和/或預防微粒物質-誘發的肺損傷

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804179A (en) 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6156320A (en) * 1993-02-05 2000-12-05 Harry Parsekian Fermented milk nutraceuticals
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
US6180100B1 (en) 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
DE69819477D1 (de) 1998-06-17 2003-12-11 Nestle Sa Mobile genetische Elemente als Werkzeuge zur genetischen Modifikation von L. delbrueckii oder L. helveticus
US6399055B1 (en) 1998-10-27 2002-06-04 Compagnie Gervais Danone Method and composition for treatment of infant diarrhea
WO2000035465A2 (en) 1998-12-11 2000-06-22 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
WO2001058465A2 (en) * 2000-02-10 2001-08-16 Gregor Reid Probiotic therapy for newborns
IL156490A0 (en) 2000-12-18 2004-01-04 Probiohealth Probiotic compounds derived from lactobacillus casei strain ke01
KR100419132B1 (ko) 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
IL157071A0 (en) 2001-02-06 2004-02-08 Nestle Sa Endotoxine binding by lactic acid bacteria and bifidobacteria
PE20030283A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
PE20030274A1 (es) 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
US20050100531A1 (en) 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
CA2490016C (en) 2002-06-28 2017-08-22 Puleva Biotech, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
EP1608383A1 (en) 2003-03-31 2005-12-28 Alimentary Health Limited A formulation comprising a bacterial strain
ATE491348T1 (de) 2003-06-23 2011-01-15 Nestec Sa Säuglingsnährpräparat oder folgemilch
US7125963B2 (en) 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
CA2559390A1 (en) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
US8926952B2 (en) 2005-04-08 2015-01-06 The Procter & Gamble Company Methods of use of probiotic bifidobacteria for human beauty benefits
CA2604338A1 (en) * 2005-04-13 2006-10-19 Nestec S.A. Infant formula with probiotics
US20060233762A1 (en) 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US20060233752A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
WO2006124630A2 (en) 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines
BRPI0808052A2 (pt) * 2007-02-28 2014-06-24 Mead Johnson Nutrition Co Método para tratar ou prevenir inflamação sistêmica.

Also Published As

Publication number Publication date
EP2114423B2 (en) 2020-01-01
PL2114423T3 (pl) 2012-10-31
EP2124977B1 (en) 2012-02-08
EP2114423A1 (en) 2009-11-11
ES2381232T3 (es) 2012-05-24
CA2679374A1 (en) 2008-09-04
EP2124977B9 (en) 2012-05-02
HK1136969A1 (en) 2010-07-16
CN101678053B (zh) 2015-12-16
MY145769A (en) 2012-04-13
TWI418355B (zh) 2013-12-11
BRPI0808145A2 (pt) 2021-03-23
US9408819B2 (en) 2016-08-09
CA2679374C (en) 2016-05-31
WO2008106373A1 (en) 2008-09-04
MX2009009119A (es) 2009-09-04
EP2124977A1 (en) 2009-12-02
RU2009135873A (ru) 2011-04-10
US9408818B2 (en) 2016-08-09
ES2388198T5 (es) 2020-07-14
RU2009135871A (ru) 2011-04-10
CA2676956A1 (en) 2008-09-04
EP2114423B1 (en) 2012-06-06
CN101678053A (zh) 2010-03-24
CN105796607A (zh) 2016-07-27
TW200900075A (en) 2009-01-01
ATE544457T1 (de) 2012-02-15
CA2676956C (en) 2017-06-13
RU2468807C2 (ru) 2012-12-10
US20080206213A1 (en) 2008-08-28
WO2008106372A1 (en) 2008-09-04
TWI494114B (zh) 2015-08-01
US20080206212A1 (en) 2008-08-28
MY151892A (en) 2014-07-14
RU2468808C2 (ru) 2012-12-10
PL2124977T3 (pl) 2012-07-31
CN101636172A (zh) 2010-01-27
HK1141729A1 (zh) 2010-11-19
MX2009008875A (es) 2009-08-28
TW200906426A (en) 2009-02-16
ES2388198T3 (es) 2012-10-10

Similar Documents

Publication Publication Date Title
BRPI0808052A2 (pt) Método para tratar ou prevenir inflamação sistêmica.
PH12014501749A1 (en) A nutritional composition comprising probiotics and improving sleep patterns
TW200507766A (en) Nutritional composition
MX2011012063A (es) Formula alimenticia para bebes y niños pequeños que comprenden probioticos para bebes y niños pequeños.
TW200612971A (en) Method for preventing or treating respiratory infections and acute otitis media in infants
BR112013016903A2 (pt) oligossacarídeos de leite humano para modular inflamação
UA100985C2 (ru) Композиция для питания с нежизнеспособной бифидобактерией и неусваиваемым олигосахаридом
NZ613165A (en) Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated fatty acids and uses thereof
BR112012003633A2 (pt) "composição nutricional que compreende cepas de bifidobacterium longum e reduz os sintomas de alergia alimentar, especialmente em bebês e crianças."
MY197622A (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
MY159072A (en) Probiotics to increase iga secretion in infants born by caesarean section
MX2009009670A (es) Reduccion de riesgo de diarrea.
CL2013001230A1 (es) Composicion a base de cereales en polvo que comprenden microorganismos probioticos no replicantes; y su uso para prevenir o tratar desordenes inflamatorios o trastornos con una defensa inmune comprometida en lactantes o niños pequeños.
BR112014001472A2 (pt) galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal
MX2009003260A (es) Probioticos para el uso en la reduccion de la incidencia y duracion de la enfermedad.
BRPI0518855A2 (pt) medicamento para aplicaÇço higiÊnica no ouvido
RS51158B (sr) Farmaceutsko jedinjenje koje sadrži bacillus coagulans i simetikon za lečenje gastrointestinalnih patologija
Chantalakhana Contribution of water buffaloes in rural development
ES1059627Y (es) Maniqui bebe para la enseñanza y practica del masaje infantil.
RU2006122217A (ru) Способ предупреждения острых респираторных вирусных инфекций у детей дошкольного возраста
UA111872U (uk) Спосіб лікування еруптивного гінгівіту у дітей
UA52520U (ru) Способ лечения нарушений функционального состояния кишечника у новорожденных и детей младенческого возраста
Martorana et al. Unless otherwise noted, the publisher, which is the American Speech-Language-Hearing Association (ASHA), holds the copyright on all materials published in Perspectives on Swallowing and Swallowing Disorders (Dysphagia), both as a compilation and as individual articles. Please see Rights and Permissions for terms and conditions of use of Perspectives content
Wallace National Chemistry Week
Бєлєнька Education Line" Child in the natural environment"

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MJN U.S. HOLDINGS LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.